An Open-Label Study to Evaluate Retreatment With LIPO-202

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02397525

Enrollment

150

Registered

2015-03-25

Start date

2015-03-31

Completion date

Unknown

Last updated

2015-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Abdominal Bulging

Brief summary

Evaluate the safety of three 8-week courses of treatment with LIPO-202 in non-obese patients who have central abdominal bulging. Efficacy measurements will also be collected.

Interventions

DRUGLIPO-202

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Provided consent * Healthy male or non-pregnant female subjects * BMI \< 30 kg/m2 * Stable diet and exercise routine * Central abdominal bulging that is at least Slight Bulge, Not Flat

Exclusion criteria

* Have had any treatment of the fat around your abdomen, including surgical procedures (tummy tuck, liposuction), injections for fat loss or treatments with devices to reduce fat in your abdomen * Plan on starting a weight loss or exercise program during the study. * Be a woman who is pregnant, breast feeding, have had a baby within 6 months and/or not using appropriate birth control. * Known hypersensitivity to study drugs * Prior or current enrollment in any Neothetics (formerly Lithera) study involving LIPO-102 or LIPO-202

Design outcomes

Primary

Measure	Time frame
Safety: vital signs, physical exams, laboratory tests	12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026